Esperion Therapeutics to be Acquired by ARCHIMED for $3.16 per Share
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 21 2025
0mins
Should l Buy ESPR?
Source: SeekingAlpha
Esperion Therapeutics Inc. is experiencing a significant price increase of 58% in pre-market trading as it crosses above the 20-day SMA.
The surge in stock price is due to Esperion entering into an acquisition agreement with ARCHIMED, where ARCHIMED will acquire Esperion for $3.16 per share in cash, valuing the transaction at approximately $1.1 billion. This deal reflects strong confidence in Esperion's future growth and includes contingent milestone payments tied to future sales performance, ensuring shareholder benefits. The acquisition is expected to enhance Esperion's position in the cardiovascular market and has been unanimously approved by its Board of Directors.
This acquisition not only provides Esperion with robust financial backing but also positions the company for significant growth in the cardiovascular and primary care markets, which could lead to enhanced leadership in treating global cardiovascular diseases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ESPR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ESPR
Wall Street analysts forecast ESPR stock price to rise
5 Analyst Rating
4 Buy
0 Hold
1 Sell
Moderate Buy
Current: 2.000
Low
1.72
Averages
7.94
High
16.00
Current: 2.000
Low
1.72
Averages
7.94
High
16.00
About ESPR
Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing and delivering cardiometabolic and rare/orphan disease therapies. It markets two oral, once-daily, non-statin therapies for patients struggling to maintain their low-density lipoprotein cholesterol (LDL-C) levels who are at risk of cardiovascular disease and nasal spray, loop diuretic for the treatment of edema associated with congestive heart failure, and hepatic and renal disease. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. NEXLETOL is a first-in-class ACLY inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating LDL receptors. NEXLIZET contains bempedoic acid and ezetimibe and lowers elevated LDL-C through complementary mechanisms of action by inhibiting cholesterol synthesis in the liver and cholesterol absorption in the intestine. Its Enbumyst is the FDA-approved nasal spray loop diuretic.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ESPERION THERAPEUTICS STOCK SOARS 57% FOLLOWING ARCHIMED'S $1.1 BILLION ACQUISITION OFFER
Stock Surge: Esperion Therapeutics shares increased by 57% following news of a potential acquisition.
Acquisition Details: The company is in discussions to acquire CoFoR for up to $1.1 billion.
See More
Monteverde Law Firm Investigates Esperion Transaction
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between Esperion Therapeutics and ARCHIMED-managed funds, with shareholders expected to receive $3.16 per share in cash, raising questions about the fairness of the deal.
- Industry Recognition: The firm has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, highlighting its expertise and success in protecting shareholder rights.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and its historical recovery records when selecting legal representation to ensure they choose the right advocate.
- Contact Information: Shareholders with concerns about the transaction or seeking more information can contact Monteverde & Associates via email or phone for free consultations, ensuring their rights are protected.
See More
Ademi LLP Investigates Esperion's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating whether Esperion breached fiduciary duties and other laws in its transaction with ARCHIMED, potentially impacting shareholder rights and corporate governance.
- Transaction Details Revealed: Esperion shareholders will receive $3.16 per share in cash at closing, along with rights to participate in up to $100 million in future sales milestone payments, with the total transaction valued at approximately $1.1 billion, indicating the company's reliance on future performance.
- Sales Performance Contingency: Additional payments tied to the sales performance of bempedoic acid products in the U.S. in 2027 include $40 million if annual sales exceed $300 million, reflecting the company's keen focus on market performance.
- Competition Restriction Clause: The transaction agreement imposes significant penalties on Esperion for accepting competing bids, which may limit the company's strategic options and affect shareholder interests.
See More
Esperion Therapeutics Shares Surge 57% on $1.1 Billion Acquisition by ARCHIMED
- Acquisition Agreement: Esperion Therapeutics has agreed to be acquired by ARCHIMED for up to $1.1 billion, with shareholders set to receive $3.16 per share in cash plus contingent value rights tied to future sales milestones worth up to $100 million, reflecting confidence in the company's growth prospects.
- Stock Surge: Following the acquisition announcement, Esperion's shares jumped approximately 57% in premarket trading, indicating a strong market reaction to the 58% premium offered and investor optimism regarding the company's future post-privatization.
- Transaction Timeline: The deal has been approved by Esperion's board and is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals, demonstrating the company's commitment to strategic transformation.
- Financial Performance Overview: Although Esperion's recent earnings report showed a GAAP EPS of $0.22, missing expectations by $0.05, its revenue of $168.45 million exceeded forecasts by $2.33 million, highlighting the company's ongoing growth potential in the cardiometabolic sector.
See More
Esperion to be Acquired at 58% Premium, Shareholders to Receive $3.16
- Acquisition Overview: Esperion has signed an acquisition agreement with Archimed for $1.1 billion, allowing shareholders to receive $3.16 per share in cash at closing, representing a 58% premium over Thursday's closing price, which provides shareholders with attractive immediate value while also offering potential upside through future milestone payments.
- Future Growth Potential: The agreement includes contingent milestone payments of up to $100 million tied to U.S. sales performance of key products, including cholesterol treatments like Nexletol and Nexlizet, which will support the company's future financial performance and growth prospects.
- Market Reaction: Following the acquisition announcement, Esperion shares surged 58% in pre-market trading on Friday and are on track to breach their 100-day moving average for the first time in nearly two months, indicating positive investor sentiment despite the stock being down over 50% year-to-date.
- Company Outlook: The acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and be delisted from Nasdaq; CEO Sheldon Koenig emphasized that this acquisition not only provides immediate value to shareholders but also retains the opportunity for additional upside through the growth of core products.
See More
Esperion to be Acquired by ARCHIMED in $1.1 Billion Deal
- Acquisition Overview: Esperion Therapeutics has announced an agreement to be acquired by funds managed by ARCHIMED in a deal valued at up to $1.1 billion, expected to close in the third quarter, marking the company's transition to private ownership and delisting from Nasdaq.
- Shareholder Benefit Analysis: Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the closing price on April 30, along with a non-tradeable contingent value right potentially worth up to $100 million in milestone payments.
- Sales Targets and Incentives: The contingent payments are tied to future U.S. net sales, with shareholders eligible for up to $40 million if bempedoic acid products (including NEXLETOL and NEXLIZET) exceed $350 million in sales by 2027, and a $60 million payment if bumetanide products (including ENBUMYST) reach or exceed $160 million in annual sales through 2030.
- Market Outlook and Strategic Significance: ARCHIMED partner Justin Bateman stated that Esperion has a strong foundation in cardiovascular and primary care markets, and the acquisition is expected to support the company's future growth, with the board unanimously approving the deal and recommending shareholders vote in favor.
See More
ESPERION THERAPEUTICS STOCK SOARS 57% FOLLOWING ARCHIMED'S $1.1 BILLION ACQUISITION OFFER
Stock Surge: Esperion Therapeutics shares increased by 57% following news of a potential acquisition.
Acquisition Details: The company is in discussions to acquire CoFoR for up to $1.1 billion.
See More
Monteverde Law Firm Investigates Esperion Transaction
- Shareholder Compensation Investigation: Monteverde & Associates is investigating the transaction between Esperion Therapeutics and ARCHIMED-managed funds, with shareholders expected to receive $3.16 per share in cash, raising questions about the fairness of the deal.
- Industry Recognition: The firm has been recognized as a Top 50 firm in the 2025 ISS Securities Class Action Services Report, highlighting its expertise and success in protecting shareholder rights.
- Legal Service Transparency: Monteverde emphasizes that shareholders should inquire about a law firm's experience in class actions and its historical recovery records when selecting legal representation to ensure they choose the right advocate.
- Contact Information: Shareholders with concerns about the transaction or seeking more information can contact Monteverde & Associates via email or phone for free consultations, ensuring their rights are protected.
See More
Ademi LLP Investigates Esperion's Transaction Compliance
- Shareholder Rights Investigation: Ademi LLP is investigating whether Esperion breached fiduciary duties and other laws in its transaction with ARCHIMED, potentially impacting shareholder rights and corporate governance.
- Transaction Details Revealed: Esperion shareholders will receive $3.16 per share in cash at closing, along with rights to participate in up to $100 million in future sales milestone payments, with the total transaction valued at approximately $1.1 billion, indicating the company's reliance on future performance.
- Sales Performance Contingency: Additional payments tied to the sales performance of bempedoic acid products in the U.S. in 2027 include $40 million if annual sales exceed $300 million, reflecting the company's keen focus on market performance.
- Competition Restriction Clause: The transaction agreement imposes significant penalties on Esperion for accepting competing bids, which may limit the company's strategic options and affect shareholder interests.
See More
Esperion Therapeutics Shares Surge 57% on $1.1 Billion Acquisition by ARCHIMED
- Acquisition Agreement: Esperion Therapeutics has agreed to be acquired by ARCHIMED for up to $1.1 billion, with shareholders set to receive $3.16 per share in cash plus contingent value rights tied to future sales milestones worth up to $100 million, reflecting confidence in the company's growth prospects.
- Stock Surge: Following the acquisition announcement, Esperion's shares jumped approximately 57% in premarket trading, indicating a strong market reaction to the 58% premium offered and investor optimism regarding the company's future post-privatization.
- Transaction Timeline: The deal has been approved by Esperion's board and is expected to close in the third quarter of 2026, pending shareholder and regulatory approvals, demonstrating the company's commitment to strategic transformation.
- Financial Performance Overview: Although Esperion's recent earnings report showed a GAAP EPS of $0.22, missing expectations by $0.05, its revenue of $168.45 million exceeded forecasts by $2.33 million, highlighting the company's ongoing growth potential in the cardiometabolic sector.
See More
Esperion to be Acquired at 58% Premium, Shareholders to Receive $3.16
- Acquisition Overview: Esperion has signed an acquisition agreement with Archimed for $1.1 billion, allowing shareholders to receive $3.16 per share in cash at closing, representing a 58% premium over Thursday's closing price, which provides shareholders with attractive immediate value while also offering potential upside through future milestone payments.
- Future Growth Potential: The agreement includes contingent milestone payments of up to $100 million tied to U.S. sales performance of key products, including cholesterol treatments like Nexletol and Nexlizet, which will support the company's future financial performance and growth prospects.
- Market Reaction: Following the acquisition announcement, Esperion shares surged 58% in pre-market trading on Friday and are on track to breach their 100-day moving average for the first time in nearly two months, indicating positive investor sentiment despite the stock being down over 50% year-to-date.
- Company Outlook: The acquisition is expected to close in the third quarter of 2026, after which Esperion will become a privately held company and be delisted from Nasdaq; CEO Sheldon Koenig emphasized that this acquisition not only provides immediate value to shareholders but also retains the opportunity for additional upside through the growth of core products.
See More
Esperion to be Acquired by ARCHIMED in $1.1 Billion Deal
- Acquisition Overview: Esperion Therapeutics has announced an agreement to be acquired by funds managed by ARCHIMED in a deal valued at up to $1.1 billion, expected to close in the third quarter, marking the company's transition to private ownership and delisting from Nasdaq.
- Shareholder Benefit Analysis: Under the agreement, Esperion shareholders will receive $3.16 per share in cash at closing, representing a 58% premium over the closing price on April 30, along with a non-tradeable contingent value right potentially worth up to $100 million in milestone payments.
- Sales Targets and Incentives: The contingent payments are tied to future U.S. net sales, with shareholders eligible for up to $40 million if bempedoic acid products (including NEXLETOL and NEXLIZET) exceed $350 million in sales by 2027, and a $60 million payment if bumetanide products (including ENBUMYST) reach or exceed $160 million in annual sales through 2030.
- Market Outlook and Strategic Significance: ARCHIMED partner Justin Bateman stated that Esperion has a strong foundation in cardiovascular and primary care markets, and the acquisition is expected to support the company's future growth, with the board unanimously approving the deal and recommending shareholders vote in favor.
See More
